Singulair Dosage/Direction for Use

Recommended Dose: MONTELUKAST (SINGULAIR) should be taken once daily. For asthma, the dose should be taken in the evening. For allergic rhinitis, the time of administration may be individualized to suit patient needs.
Patients with both asthma and allergic rhinitis should take only one tablet daily in the evening.
Adults 15 Years of Age and Older with Asthma and/or Allergic Rhinitis: The dosage for adults 15 years of age and older is one 10-mg film-coated tablet daily.
Pediatric Patients 6 to 14 Years of Age with Asthma and/or Allergic Rhinitis: The dosage for pediatric patients 6 to 14 years of age is one 5-mg chewable tablet daily.
Pediatric Patients 2 to 5 Years of Age with Asthma and/or Allergic Rhinitis: The dosage for pediatric patients 2 to 5 years of age is one 4-mg chewable tablet daily or one packet of 4-mg oral granules daily.
Pediatric Patients 6 Months to 2 Years of Age with Asthma or Perennial Allergic Rhinitis: The dosage for pediatric patients 6 months to 2 years of age is one packet of 4-mg oral granules daily.
Administration of oral granules: MONTELUKAST (SINGULAIR) oral granules can be administered either directly in the mouth, mixed with a spoonful of cold or room temperature soft food (e.g., applesauce), or dissolved in 1 teaspoonful (5mL) of cold or room temperature baby formula or breast milk. The packet should not be opened until ready to use. After opening the packet, the full dose of MONTELUKAST (SINGULAIR) oral granules must be administered immediately (within 15 minutes). If mixed with food, or dissolved in baby formula or breast milk, MONTELUKAST (SINGULAIR) oral granules must not be stored for future use. MONTELUKAST (SINGULAIR) oral granules are not intended to be dissolved in any liquid other than baby formula or breast milk for administration. However, liquids may be taken subsequent to administration.
General Recommendations: The therapeutic effect of MONTELUKAST (SINGULAIR) on parameters of asthma control occurs within one day. MONTELUKAST (SINGULAIR) tablets, chewable tablets, and oral granules can be taken with or without food. Patients should be advised to continue taking MONTELUKAST (SINGULAIR) while their asthma is controlled, as well as during periods of worsening asthma.
No dosage adjustment is necessary for pediatric patients, for the elderly, for patients with renal insufficiency, or mild-to-moderate hepatic impairment, or for patients of either gender.
Therapy with MONTELUKAST (SINGULAIR) in Relation to Other Treatments for Asthma: MONTELUKAST (SINGULAIR) can be added to a patient's existing treatment regimen.
Reduction in Concomitant Therapy: Bronchodilator Treatments: MONTELUKAST (SINGULAIR) can be added to the treatment regimen of patients who are not adequately controlled on bronchodilator alone. When a clinical response is evident (usually after the first dose), the patient's bronchodilator therapy can be reduced as tolerated.
Inhaled Corticosteroids: Treatment with MONTELUKAST (SINGULAIR) provides additional clinical benefit to patients treated with inhaled corticosteroids. A reduction in the corticosteroid dose can be made as tolerated. The dose should be reduced gradually with medical supervision. In some patients, the dose of inhaled corticosteroids can be tapered off completely. MONTELUKAST (SINGULAIR) should not be abruptly substituted for inhaled corticosteroids.
Mode of Administration: MONTELUKAST (SINGULAIR) should be taken orally. For asthma, the dose should be taken in the evening. For allergic rhinitis, the time of administration may be individualized to suit patient needs.
Patients with both asthma and allergic rhinitis should take only one tablet daily in the evening.